fda glp-1 compounding warning october 2025 Compounded weight-loss and hormone drugs are booming, but experts say regulators have little visibility into who is taking them or what side effects they may be causing. ⁠ ⁠ Critics warn that Medscape | The FDA has

Pretrial Proceedings Once transferred, the assigned judge manages all pretrial proceedings

Clinical implication The updated FDA labeling for liraglutide and semaglutide highlights the importance of monitoring depressive symptoms or suicidal thoughts, suggesting treatment discontinuation if such ideations occur [87,88]

RELATED: New GLP-1 drugs could suppress desire for more than just food, study suggests The rapid rise in GLP-1 usage continues to align with broader improvements in national health, particularly aiding in lowering obesity rates

For more on managing early symptoms, read our blog on GLP-1 side effects: nausea, digestive changes, and when to call a clinician